Holen Sie sich die Stockscreener-App
826.28
0.95%
7.78
Vorhandelsmarkt:
826.53
0.25
+0.03%
Schlusskurs vom Vortag:
$818.50
Offen:
$815.64
24-Stunden-Volumen:
335.50K
Relative Volume:
0.90
Marktkapitalisierung:
$50.57B
Einnahmen:
$3.06B
Nettoeinkommen (Verlust:
$1.28B
KGV:
42.00
EPS:
19.6719
Netto-Cashflow:
$447.35M
1W Leistung:
-0.43%
1M Leistung:
+3.28%
6M Leistung:
+27.18%
1J Leistung:
+38.74%
1-Tages-Spanne:
$809.14
$832.38
1-Wochen-Bereich:
$749.75
$842.18
52-Wochen-Spanne:
$510.06
$855.46
Argen X Se Adr Stock (ARGX) Company Profile
Vergleichen Sie ARGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Fortgesetzt | Truist | Buy |
| 2025-09-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Strong Buy |
| 2024-10-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-06-15 | Eingeleitet | Societe Generale | Sell |
| 2023-05-31 | Eingeleitet | UBS | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Eingeleitet | William Blair | Outperform |
| 2022-10-12 | Eingeleitet | Oppenheimer | Perform |
| 2022-07-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Fortgesetzt | Stifel | Buy |
| 2022-05-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-23 | Hochstufung | Redburn | Neutral → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Eingeleitet | Deutsche Bank | Hold |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-18 | Eingeleitet | UBS | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Eingeleitet | Redburn | Neutral |
| 2021-03-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-02-10 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-10-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-27 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-09-16 | Fortgesetzt | Cowen | Outperform |
| 2019-06-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-18 | Fortgesetzt | SunTrust | Buy |
| 2019-01-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-12-17 | Eingeleitet | Goldman | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-06-29 | Eingeleitet | Nomura | Buy |
| 2018-04-09 | Eingeleitet | SunTrust | Buy |
| 2018-01-29 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
Vyvgart Fuels Strong Growth for Argenx and Supports Developing Pipeline - Morningstar
argenx SE stock price target raised to $1,146 from $800 at TD Cowen - Investing.com Philippines
argenx ADR earnings beat by $0.74, revenue topped estimates - Investing.com Canada
Argenx rises after Q3 earnings beat on strong sales growth By Investing.com - Investing.com South Africa
Argenx rises after Q3 earnings beat on strong sales growth - Investing.com India
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update - Sahm
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients - GlobeNewswire Inc.
Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 - Sahm
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Argx stock hits all-time high at 821.97 USD By Investing.com - Investing.com Philippines
Argx stock hits all-time high at 821.97 USD - Investing.com India
TD Cowen Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
argenx stock price target maintained at $800 by TD Cowen on strong Vyvgart uptake - Investing.com
Argenx Se (ARGX) Gets a Buy from Evercore ISI - The Globe and Mail
How Do Investors Really Feel About argenx SE? - Sahm
RBC Capital Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
Argenx SE Sponsored ADR (ARGX) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
Stocks Showing Improved Relative Strength: Zai Lab ADR - inkl
Argenx NV stock hits all-time high at 803.95 USD By Investing.com - Investing.com South Africa
Argenx NV stock hits all-time high at 803.95 USD - Investing.com
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - 富途牛牛
Argenx SE Calls Extraordinary Shareholder Meeting for November 2025 - The Globe and Mail
Structure Therap ADR Earns Relative Strength Rating Upgrade - inkl
Goldman Sachs Sticks to Its Buy Rating for Argenx Se (ARGX) - The Globe and Mail
Argenx stock hits all-time high at 781.12 USD By Investing.com - Investing.com Australia
Argenx stock hits all-time high at 781.12 USD - Investing.com
Argenx Se (ARGX) Receives a Buy from RBC Capital - The Globe and Mail
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm
Barclays Sticks to Its Buy Rating for Lonza Group Ltd (LONN) - The Globe and Mail
Price Over Earnings Overview: argenx - Sahm
Leerink Partners Keeps Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Barclays Sticks to Their Hold Rating for Roche Holding AG (RHHVF) - The Globe and Mail
Argenx Se (ARGX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Oppenheimer reaffirms Outperform rating on argenx stock after positive data - Investing.com
Truist Securities reiterates Buy rating on argenx stock with $918 target - Investing.com
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Truist Securities assumes coverage on argenx stock with Buy rating - Investing.com
Deutsche Bank downgrades Argenx to “hold” after 40% rally, €655 PT intact - Investing.com
14 Newly Overvalued Stocks for the Week - Morningstar
BofA Securities reaffirms Buy rating on argenx stock with $887 target - Investing.com
Argenx stock hits all-time high at 716.89 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Piper Sandler raises argenx stock price target to $820 on Vyvgart success - Investing.com
European Stocks Slip Slightly In US Trading To Start The Week - Finimize
Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily
Argenx stock reaches all-time high at 696.94 USD - Investing.com
Argenx: study met primary endpoint - AInvest
Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest
Finanzdaten der Argen X Se Adr-Aktie (ARGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.82%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):